CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Executive Officer sold 14,435 shares at an average $42.70 ($616,349)
- 4 Open-market sale General Counsel and Secretary sold 3,966 shares at an average $42.67 ($169,242)
- 4 Open-market sale Chief Operating Officer sold 1,388 shares at an average $42.54 ($59,050)
- 4 Open-market buy Director bought 7,000 shares at $44.85 ($313,948)
- 4 Planned sale Chief Executive Officer sold 18,360 shares at $55.21 ($1,013,564)
- 4 Open-market sale Chief Operating Officer sold 333 shares at $52.80 ($17,582)
- 4 Planned sale Chief Executive Officer sold 18,568 shares at an average $54.21 ($1,006,580)
- 4 Open-market sale General Counsel and Secretary sold 11,542 shares at an average $53.67 ($619,492)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-K Report Annual Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Option exercise Chief Executive Officer acquired 13,751 shares (option exercise)
- SC 13G/A Stake Amended Statement of Ownership
- 4 Planned sale Chief Executive Officer sold 15,000 shares at $55.10 ($826,565)
- 4 Planned sale Chief Executive Officer sold 30,000 shares at an average $55.62 ($1,668,678)
- 144 Insider Sale of Securities
Page 8 of 45 · 883 filings